Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer
06 juil. 2022 16h01 HE
|
Calithera Biosciences, Inc.
-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences,...
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma
23 juin 2022 16h05 HE
|
Calithera Biosciences, Inc.
-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes -- Study will evaluate SYK inhibitor both in patients with wild-type disease and...
Calithera Biosciences Announces 1-for-20 Reverse Stock Split
14 juin 2022 12h50 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it has...
Calithera to Present at the H.C. Wainwright Global Investment Conference
17 mai 2022 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan...
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
10 mai 2022 16h05 HE
|
Calithera Biosciences, Inc.
-- Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 -- SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc....
Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
03 mai 2022 16h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the...
Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds
08 avr. 2022 13h01 HE
|
Calithera Biosciences, Inc.
Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous solid tumor cancers VPS4A and VPS4B are gene...
Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
31 mars 2022 16h05 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...
Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock
30 mars 2022 02h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced the...
Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock
29 mars 2022 16h01 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it...